About SH PIONEER HLDG Company

China Pioneer Pharmaceutical Holdings Co., Ltd. (the “Company” and its subsidiaries collectively referred to as the “Group”), the Group is one of China's largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceuticals and medical devices. Since the establishment of the company in 1996, the Group has upheld the development concept of global thinking and localized management, and introduced a series of products representing the international advanced level of technology to the domestic pharmaceutical market. On 2013/11/5, the Group was successfully listed on the Hong Kong Main Board, stock code HK.01345. As of June 30, 2015, the Group's pharmaceutical products include ophthalmology, analgesia, cardiovascular, respiratory diseases, gastrointestinal diseases, immunology and other therapeutic fields. Medical device products cover four treatment fields, including ophthalmology, dentistry, and wound care. At the same time, the market value of corporate agency brands increased rapidly. As an up-and-coming pharmaceutical company with a global vision, in developing the international market, the Group has not only established stable and mutually beneficial long-term cooperative relationships with many internationally renowned pharmaceutical and medical device companies, including Alcon of the United States, Alfa Weissman of Italy, Taimler of Germany, Orion of Finland, Polichem of Switzerland, Covex of Germany, Qualimed of Germany, NovaBay of the United States, etc., and has successfully established long-term cooperative relationships overseas for the company's future sustainable development. A complete and effective product introduction cooperation network. In terms of establishing a sales network in China, relying on the Group's strong sales team and the company's long-term promotion of a win-win cooperative culture, the Group has established a sales system covering all parts of the country and has established stable cooperative relationships with more than 500 pharmaceutical companies across the country. As of 2015/6/30, the Group's products have achieved effective coverage in more than 29,000 hospitals and medical institutions and 105,000 pharmacies across the country, and it has a clear advantage in the industry. Furthermore, the Group is gradually implementing a globalization strategy. We have already begun to build markets and sales areas in the Southeast Asia region, and we have also invested in overseas partners one after another. The Group has successively purchased part of the shares of NovaBay Pharmaceuticals (NovaBay Pharmaceuticals), a high-end American wound care company, and Q3, a German stent catheter medical device company. Through these investments, the Group has further deepened cooperation with overseas partners and is also gradually moving towards the goal of an international company. In the future, the Group is committed to turning itself into a new pharmaceutical marketing enterprise that outsources production and R&D to foreign companies and has its own domestic sales channels and product pricing power. We believe that in the current era of rapid development of China's pharmaceutical industry, with a highly open development mentality, forward-looking ability to introduce new products and precise product positioning, complemented by a complete marketing network and an efficient business management system, the Group's development goals will surely be achieved.